Malignant insulinoma: Recommendations for characterisation and treatment
Éric Baudin(Institut Gustave Roussy), Christine Do Cao(Centre Hospitalier Universitaire de Lille), Yves Reznick(Centre Hospitalier Universitaire de Caen Normandie), Delphine Vezzosi(Université Toulouse III - Paul Sabatier), David Taïeb(Aix-Marseille Université), Pierre Goudet(Inserm), Guillaume Cadiot(Centre Hospitalier Universitaire de Reims), Jean‐Yves Scoazec(Université Paris-Saclay), Catherine Lombard‐Bohas(Hospices Civils de Lyon), Antoine Tabarin(Université de Bordeaux), Françoise Borson‐Chazot(Hospices Civils de Lyon), Philippe Caron(Hôpital Larrey), Emmanuel Mitry(Roche (Switzerland)), François Pattou(Inserm)
Cited by 67
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors
|European Journal of Endocrinology|2016|1.5k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
|Neuroendocrinology|2012|869
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
|Cancer Cell|2017|791